EP Wealth Advisors LLC Has $9.33 Million Stock Position in Pfizer Inc. (NYSE:PFE)

EP Wealth Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 0.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 336,062 shares of the biopharmaceutical company’s stock after acquiring an additional 2,864 shares during the quarter. EP Wealth Advisors LLC’s holdings in Pfizer were worth $9,326,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PFE. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $212,000. Trust Co of the South bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $802,000. ARK Investment Management LLC increased its holdings in shares of Pfizer by 7.7% during the fourth quarter. ARK Investment Management LLC now owns 499,757 shares of the biopharmaceutical company’s stock valued at $14,388,000 after acquiring an additional 35,677 shares in the last quarter. Jacobs & Co. CA increased its holdings in shares of Pfizer by 1.6% during the fourth quarter. Jacobs & Co. CA now owns 330,023 shares of the biopharmaceutical company’s stock valued at $9,501,000 after acquiring an additional 5,190 shares in the last quarter. Finally, First Pacific Financial increased its holdings in shares of Pfizer by 7.3% during the fourth quarter. First Pacific Financial now owns 20,716 shares of the biopharmaceutical company’s stock valued at $596,000 after acquiring an additional 1,418 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 3.4 %

Shares of PFE stock traded up $1.01 during trading hours on Friday, reaching $30.77. The company’s stock had a trading volume of 34,288,306 shares, compared to its average volume of 39,686,719. The stock has a market capitalization of $174.36 billion, a P/E ratio of -513.91, a P/E/G ratio of 1.17 and a beta of 0.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.19. The firm’s fifty day simple moving average is $28.50 and its 200 day simple moving average is $27.76. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.23 EPS. Equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.46%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, July 10th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Barclays boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.